$MNKD News
Last published 1d ago
- 1d agoMNKDMannKind to Participate in Upcoming Investor ConferencesGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Chris Prentiss, will provide a business update at two upcoming investor conferences in London.
- 6d agoMNKDMANNKIND CORP - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoMNKDMannKind Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ3 2026 total revenues of $101.9 million, +24% vs. Q3 2025Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 Furoscix ReadyFlow™ was approved and shipments commenced mid-September Rapid
- 1w agoMNKDMannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026GlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will report third quarter 2026 financial results after market close on
- 3w agoMNKDCompany Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, Bronchiectasis & COPD Innovation - MANNKIND CORPEarnings Call Transcriptsall right um all right everyone thanks uh we're you know been a long and busy day a fun day a lot of learnings and i know we're all getting a little tired but uh this is going to be an exciting one i i promise um so dr d
- 4w agoMNKDMannKind to Participate in the Chardan Healthcare ConferenceGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on
- 1mo agoMNKDMannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)GlobeNewswireNew analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across injection sites support
- 2mo agoMNKDMannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight ManagementGlobeNewswireCollaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing
- 2mo agoMNKDMannKind to Present at Upcoming Investor ConferencesGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that members of the MannKind management team will present at the following upcoming
- 3mo agoMNKDMannKind Corporation Q2 2026 Earnings Call - MANNKIND CORPEarnings Call TranscriptsGood afternoon, and welcome to the Mankind Corporation second quarter 2026 financial results earnings call. As a reminder, this call is being recorded on August 5th, 2026, and will be available for replay on the M mankin
- 3mo agoMNKDMANNKIND CORPORATION Q2 2026 EARNINGS CALL - MANNKIND CORPEarnings Call TranscriptsGood afternoon, and welcome to the Mankind Corporation second quarter 2026 financial results earnings call. As a reminder, this call is being recorded on August 5th, 2026, and will be available for replay on the M mankin
- 3mo agoMNKDMannKind Corporation Q2 2026 Earnings Call - MANNKIND CORPEarnings Call TranscriptsGood afternoon, and welcome to the Mankind Corporation second quarter 2026 financial results earnings call. As a reminder, this call is being recorded on August 5th, 2026, and will be available for replay on the M mankin
- 3mo agoMNKDMannKind Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAchieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive
- 3mo agoMNKDINFLO‑1 Data Readout: Strengthening the Nintedanib DPI Opportunity in IPF - MANNKIND CORPEarnings Call TranscriptsGood afternoon and welcome to the Mankind Corporation conference call to discuss the Phase 1b results for an attentive DPI. As a reminder, this call is being recorded on July 29, 2026 and will be available for replay on
- 3mo agoMNKDINFLO‑1 Data Readout: Strengthening the Nintedanib DPI Opportunity in IPF - MANNKIND CORPEarnings Call TranscriptsGood afternoon and welcome to the Mankind Corporation conference call to discuss the Phase 1b results for an attentive DPI. As a reminder, this call is being recorded on July 29, 2026 and will be available for replay on
- 3mo agoMNKDMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFGlobeNewswireGenerally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with
- 3mo agoMNKDMannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026GlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that the Company will report second quarter 2026 financial results after market close
- 3mo agoMNKDU.S. FDA Approval of Furoscix ReadyFlow - MANNKIND CORPEarnings Call TranscriptsGood morning and welcome to the Mankind Corporation conference call to discuss the U.S. FDA approval of Furo6 ReadyFlow. As a reminder, this call is being recorded on July 24, 2026 and will be made available for replay o
- 3mo agoMNKDMannKind Announces $50 Million Private PlacementGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative,
- 3mo agoMNKDMannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney DiseaseGlobeNewswireTransformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital settingDelivers IV-equivalent diuretic effect through
- 4mo agoMNKDMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DGlobeNewswireCollaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) --
- 5mo agoMNKDData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsGlobeNewswireBuilds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety,
- 5mo agoMNKDMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFGlobeNewswirePhase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on
- 5mo agoMNKDMannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of
- 5mo agoMNKDMannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesGlobeNewswireEnables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new
- 5mo agoMNKDMannKind to Present at Jefferies Global Healthcare ConferenceGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside
- 5mo agoMNKDMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) SystemsGlobeNewswireNew analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancyLate-breaking comparative data vs. rapid-acting insulin
- 6mo agoHIMSNVOMNKDDNAThe $59B Quiet Shift Reshaping How Patients Access CarePR NewswirePoint-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab ...
- 6mo agoMNKDMannKind Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program updates:
- 6mo agoMNKDMannKind Corporation Q1 2026 Earnings Call - MannKind CorporationEarnings Call TranscriptsGood morning and welcome to the Mankind Corporation 4th Quarter and Full Year 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2026 and will be available for replay on the
- 6mo agoMNKDUTHRMannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung DiseasesGlobeNewswireThe formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited
- 6mo agoMNKDMannKind to Report First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative,
- 7mo agoMESOLGVNLCTXMNKDA Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.PR NewswireEquity-Insider.com — There is a key "master" protein in your body called α-Klotho. You've probably never heard of it. But the scientific community...
- 8mo agoMNKDMannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026GlobeNewswirePresentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1DData to be featured across oral and poster
- 8mo agoMNKDMannKind Announces Settlement of Convertible Senior NotesGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50%
- 8mo agoMNKDMannKind to Participate in Upcoming Investor ConferencesGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind's Chief
- 8mo agoMNKDMannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully
- 8mo agoMNKDMannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share
- 8mo agoMNKDMannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative,
- 9mo agoMNKDMannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)GlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative,
- 9mo agoMNKDALTLCTXARWRLongevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR NewswireUSA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion...
- 9mo agoVRTXFATEMNKDARDXBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsPR NewswireThe medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for...
- 9mo agoMNKDMannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyGlobeNewswireUpdated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind
- 9mo agoMNKDApproval of Afrezza, Bla #022472FDA Approved DrugsApproval Date: 01/26/2026; Drug Name: Afrezza, Bla #022472; Active Ingredients: INSULIN RECOMBINANT HUMAN; Company: Mannkind; Submission Status: Approval; Application Number: 022472
- 9mo agoARDXAVAIFATEMNKD+1Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsGlobeNewswireVANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven
- 10mo agoMNKDMannKind Provides Business Updates and 2026 Growth DriversGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative,
- 10mo agoMNKDMannKind Shares FUROSCIX® Business UpdatesGlobeNewswireFDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025
- 11mo agoMNKDMannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney DiseaseGlobeNewswireIf approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address
- 1y agoMNKDMannKind to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial
- 1y agoMNKDMannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung DiseaseGlobeNewswireMannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility